ScoreWhy is ImmunityBio, Inc. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate -215.10% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -38.35
2
With a growth in Net Sales of 59.99%, the company declared Very Positive results in Jun 25
- The company has declared positive results for the last 4 consecutive quarters
- NET PROFIT(HY) Higher at USD -191.73 MM
- NET SALES(Q) Highest at USD 26.43 MM
- OPERATING PROFIT MARGIN(Q) Highest at -255.08 %
3
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -58.73%, its profits have risen by 6.6%
4
Majority shareholders : Mutual Funds
5
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -58.73% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to ImmunityBio, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is ImmunityBio, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
ImmunityBio, Inc.
-49.56%
-0.75
88.64%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
124.92%
EBIT Growth (5y)
-215.10%
EBIT to Interest (avg)
-38.35
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.23
Sales to Capital Employed (avg)
0.05
Tax Ratio
0.06%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
13.24%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-4.70
EV to EBIT
-11.19
EV to EBITDA
-11.83
EV to Capital Employed
25.72
EV to Sales
112.38
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-229.71%
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend24What is working for the Company
NET PROFIT(HY)
Higher at USD -191.73 MM
NET SALES(Q)
Highest at USD 26.43 MM
OPERATING PROFIT MARGIN(Q)
Highest at -255.08 %
RAW MATERIAL COST(Y)
Fallen by -126.04% (YoY
-2What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for ImmunityBio, Inc.
Net Sales
At USD 26.43 MM has Grown at 238.54%
over average net sales of the previous four periods of USD 7.81 MMMOJO Watch
Near term sales trend is extremely positive
Net Sales (USD MM)
Net Sales
Highest at USD 26.43 MM and Grown
In each period in the last five periodsMOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Operating Profit Margin
Highest at -255.08 % and Grown
In each period in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Net Profit
Higher at USD -191.73 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Raw Material Cost
Fallen by -126.04% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
